Visceral leishmaniasis (VL) is a serious parasitic disease causing considerable mortality
and major disability in the Indian subcontinent. It is most neglected tropical disease …

Leishmaniasis is a parasitic disease that encompasses a range of clinical manifestations
affecting people in tropical and subtropical regions of the world. Epidemiological and …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

Abstract Background. Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is
currently the first-line therapy in the VL elimination program of the Indian subcontinent …

Miltefosine is an alkylphosphocholine agent with a broad spectrum of antiparasitic
properties. For over two decades, miltefosine has remained the only oral drug licensed and …

Background Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are
increasingly being reported. However, there has been no laboratory confirmed reports of …

Background The South-East Asia Region Kala-azar Elimination Programme (KAEP) is
expected to enter the consolidation phase in 2017, which focuses on case detection, vector …

Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …

Leishmaniasis is a vector borne protozoan disease and it remains a major public health
problem world-wide. Lack of an effective vaccine and vector control program makes the …

Background. Recent reports indicated high miltefosine treatment failure rates for visceral
leishmaniasis (VL) on the Indian subcontinent. To further explore the pharmacological …